Search: WFRF:(Tiensuu Janson Eva)
> (1995-1999) >
Treatment with high...
Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors : evaluation of therapeutic and toxic effects
-
- Tiensuu Janson, Eva (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg
-
- Eriksson, Barbro (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg
-
- Öberg, Kjell (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg
-
show more...
-
- Skogseid, Britt (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi, K Öberg
-
- Öhrvall, Ulf (author)
- Uppsala universitet,Endokrinkirurgi
-
- Nilsson, Sten (author)
- Uppsala universitet,Enheten för onkologi
-
- Westlin, Jan-Eric (author)
- Uppsala universitet,Enheten för onkologi
-
show less...
-
(creator_code:org_t)
- 2009-07-08
- 1999
- English.
-
In: Acta Oncologica. - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 38:3, s. 373-377
- Related links:
-
https://www.tandfonl...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Carcinoid tumors and endocrine pancreatic tumors often express somatostatin receptors (sst). Tumor spread may be visualized by sst scintigraphy using [(111)In-DTPA-D-Phe1]-octreotide. In this study, tumor targeting therapy with [(111)In-DTPA-D-Phe1]-octreotide at high doses (6 GBq every third week) was used to treat patients with sst-expressing tumors. Five patients entered the protocol and three were evaluable for response, while all could be evaluated for toxicity. Two patient responded with a significant reduction in tumor markers (> 50%). The third patient showed increasing levels of tumor markers. Side effects were expressed as depression of bone-marrow function. In one patient a grade 4 reduction in platelet count was observed requiring several thrombocyte transfusions. In another two patients platelet counts decreased significantly. We conclude that treatment with [(111)In-DTPA-D-Phe1]-octreotide can be used in patients with neuroendocrine tumors but blood parameters have to be carefully monitored to avoid severe side effects.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database